Analyzing multi-omics data for personalized treatment of fatty liver disease linked to obesity
Integrated Multi-omics and Machine Learning-driven Personalized Treatment of Obesity-associated Fatty Liver Disease
This study is trying to see if using advanced data analysis can help create personalized treatments for people with fatty liver disease caused by obesity.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1104 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut Investigacio Sanitaria Pere Virgili Academic / other |
| Locations | 1 site (Reus, Tarragona) |
| Trial ID | NCT05554224 on ClinicalTrials.gov |
What this trial studies
This study aims to analyze samples from patients with obesity-associated fatty liver disease using a multi-omics approach, integrating clinical information and genetic variants. The goal is to develop predictive models through artificial intelligence algorithms to better understand the disease's progression and underlying causes. By addressing the challenges of diagnosing and treating metabolic dysfunction-associated fatty liver disease (MAFLD), the study seeks to improve patient outcomes and therapeutic strategies. The research focuses on the significant health impacts of obesity and diabetes, which contribute to liver disease.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a body mass index of 35 or higher, particularly those with obesity-related comorbidities.
Not a fit: Patients with current cancer diagnoses, severe illnesses, or those consuming drugs or alcohol may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnostic tests and personalized treatment options for patients with obesity-associated fatty liver disease.
How similar studies have performed: Other studies have shown promise in using multi-omics approaches for understanding complex diseases, suggesting potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Body mass index greater or equal to 40 kg/m\^2. * Body mass index between 35 and 40 kg/m\^2 with high-risk comorbidities (diagnosis or treatment for hypertension, dyslipidemia, or type 2 diabetes mellitus). * Positive psychiatric evaluation. * Age greater or equal to 18 years old. Exclusion Criteria: * Legal or illegal drug consumption, including alcohol. * Diagnosis of Hepatitis. * Current cancer diagnosis or treatment. * Clinical or analytical evidence of severe illness. * Clinical or analytical evidence of chronic or acute inflammation. * Clinical or analytical evidence of infectious diseases. * Clinical or analytical evidence of terminal illness.
Where this trial is running
Reus, Tarragona
- Hospital Universitari Sant Joan — Reus, Tarragona, Spain (Recruiting)
Study contacts
- Principal investigator: Jorge Joven, Professor — Institut Investigacio Sanitaria Pere Virgili
- Study coordinator: Jorge Joven, Professor
- Email: jorge.joven@urv.cat
- Phone: +34977310300
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.